ANAEROBİK YUMUŞAK DOKU İNFEKSİYONLARININ TEDAVİSİ

Anaerobik infeksiyonların tedavisi hızlı ve uygun olmalıdır. Tedavi yaklaşımı hiperbarik oksijen, cerrahi ve antimikrobiyal tedaviyi içerir. Son beş yıl içerisinde anaerobik infeksiyonlara etkili yeni ajanlar kullanıma sunulmuştur. Bununla birlikte anaerobik organizmalara karşı antibiyotik direnci gittikçe artmaktadır. Yumuşak doku infeksiyonlarında hiperbarik oksijen tedavisi sıklıkla antibiyotik tedavisi ile birlikte kullanılmaktadır. Bu makaledeki amacımız anaerobik yumuşak doku infeksiyonlarında yeni tedavi yaklaşımlarını vurgulamaktır.

Anahtar Kelimeler:

Anaerobik infeksiyonlar, Antimikrobiyal tedavi, Hiperbarik oksijen tedavisi

TREATMENT OF ANAEROBIC SOFT – TISSUE INFECTIONS

The treatment of anaerobic infection needs to be prompt and appropriate in order to ensure recovery. Management includes the use of hyperbaric oxygen, surgical methods and antimicrobial therapy. In the past five years, newer agents effective against anaerobic organisms were introduced. However antibiotic resistance is increasingly common against anaerobic bacteria. Hyperbaric oxygen therapy is often combined with antibiotic therapy for soft-tissue infections. The purpose of this paper was to accent treatment of anaerobic softtissue infections and new approaches.

Keywords:

Anaerobic infection, Antimicrobial therapy, Hyperbaric oxygen,

PDF

___

[1] Brook I. Management of anaerobic infection. Expert Rev Anti Infect Ther 2004;2:153-158
[2] Lipsky BA, Berendt AR, Dery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.
[3] International Working Group on the Diabetic Foot . International consensus on the diabetic foot (CD-Rom). Brussels International Diabetes Foundation, May 2003.
[4] Olsen I, Solberg CO, Finegold SM. A primer on anaerobic bacteria and anaerobic infections for the uninitiated. Infection 1999;27:159-/65.
[5] Giamarellou H. Anaerobic infection therapy. Int J Antimicrob Agents 2000;16:341-6.
[6] Fang H, Edlund C, Hedberg M, Nord CE. New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group. Int J Antimicrob Agents 2002;19:361-70.
[7] Behra-Miellet J, Calvet L, Mory F et al. Antibiotic resistance among anaerobic Gram-negative bacilli:lessons from a French multicentric survey. Anaerobe 2003;9:105-111.
[8] Ulger (Toprak) N, Celik C, Cakici O, Soyletir G. Antimicrobial susceptibilities of Bacteroides fragilis and Bacteroides thetaiotaomicron strains isolated from clinical specimens and human intestinal microbiota. Anaerobe 2004;10:255-9.
[9] Koeth LM, Good CE, Appelbaum PC et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 2004;53(6):1039-1044.
[10] Stein GE, Goldstein EJC. Review of the in vitro activity and potential clinical efficacy of levofloxacin in the treatment of anaerobic infections. Anaerobe 2003;9:75-81.
[11] Brazier JS, Hall V, Morris TE et al. Antibiotic susceptibilities of Gram-positive anaerobic cocci: results of a sentinel study in England and Wales. Journal of Antimicrobial Chemotherapy 2003;52:224-8.
[12] Goldstein EJC, Citron DM, Merriam CV et al. General Microbiology and In Vitro Susceptibility of Anaerobes Isolated from Complicated Skin and Skin-Structure Infections in Patients Enrolled in a Comparative Trial of Ertapenem Versus Piperacillin-Tazobactam. Clin Infect Dis 2002;35:119-25.
[13] Goldstein EJC, Citron DM, Merriam CV et al. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. Journal of Antimicrobial Chemotherapy 2002;50:411-20.
[14] Şen Z, Yomruk E, Kaya B ve ark. Fournier gangreninde tedavi prensipleri. Ankara Ü. Tıp Fakültesi Mecmuası 2003;56:249-58.
[15] Elliott D, Kufera JA, Myers RAM. The Microbiology of Necrotizing Soft Tissue Infections. Am J Surg 2000;179:361-6.
[16] Giamarellou H. Anaerobic infection therapy. Int J Antimicrob Agents 2000;16:341-6.
[17] Teng LJ, Hsueh PR, Tsai JC et al. High Incidence of Cefoxitin and Clindamycin Resistance among Anaerobes in Taiwan. Antimicrob Agents Chemother 2002;46:2908-13.
[18] Credito KL, Jacobs MR, Appelbaum PC.Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole. Diagn Microbiol Infect Dis 2000;38:181–3.
[19] Kindwall EP. A history of hyperbaric medicine. In: Kindwall EP (ed.) Hyperbaric Medicine Practice, Arizona, Best Publishing Company 1994; 2-16.
[20] Aktaş Ş. Anaerobik infeksiyonlarda hiperbarik oksijen tedavisi. Ankem Derg 2001;15: 611-616.
[21] Fielden MP, Martinovic BE, Ells AL. Hyperbaric oxygen therapy in the treatment of orbital gas gangrene. Journal of AAPOS 2002 ;6:252-254.
[22] Demello FJ, Haglin JJ, Hitchcock CR. Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery and hyperbaric oxygen. Surgery 1973;73:936-941.
[23] Rudge FW. The role of hyperbaric oxygenation in the treatment of clostridial myonecrosis. Mil Med 1993;158:80-83.
[24] Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996;334:1642-48.
[25] Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg 2004;139:1339-45.
[26] Sugihara A, Watanabe H, Oohashi M et al. The effect of hyperbaric oxygen therapy on the bout of treatment for soft tissue infections. J Infect 2004;48:330-333.
[27] Nichols RL, Florman S. Clinical Presentations of Soft-Tissue Infections and Surgical Site Infections. Clin Infect Dis 2001;33:85-93.
[28] Taviloğlu K, Cabıoğlu N, Çağatay A, Özsüt H. Nekrotizan fasiitis, II. Ulusal Travma ve Acil Cerrahi Kongresi. Bildiri özetleri 1999;139.
[29] Kalani M, Jörneskog G, Naderi N et al. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers Long-term follow-up. J Diabet Complications 2002;16:153-158.